Ominimo has successfully completed its Series B funding round, raising $22.5 million. This round allowed the company to reach a valuation of $1.6 billion just two years after launch, making it one of the fastest-growing unicorns in the European insurtech sector.
Unlike several other fast-funded tech startups in Europe that focus on market size at the expense of profit margins, Ominimo has managed to achieve profitability while continuing to grow its customer base and expand across Europe.
Ominimo is based in Budapest and was founded in 2024 by Dusan Komar, Dennis Weinberger, Laslo Horvat, and Kristina Kozina. The company's main focus is modernizing vehicle insurance through the use of advanced data, process automation, and artificial intelligence technologies.
Ominimo is preparing to enter the US market while accelerating long-term international growth and regulatory compliance initiatives. Currently, the company provides insurance services in Hungary, Poland, the Netherlands, and Sweden, and plans further expansion. Operations will soon begin in Belgium and Romania, followed by plans to enter the Spanish, Italian, and French markets. Management aims for a successful launch of Ominimo's insurance services in the US market by 2027.
Obtaining its own insurance license is a key strategic goal. Currently, Ominimo operates as an managing general agent, handling pricing, customer acquisition, and claims management, while underwriting risk is borne by partner insurers. Transitioning to a licensed model will allow the company to retain a larger share of underwriting profit and gain greater control over product development, although this will also require significantly more regulatory capital.
Ominimo has distinguished itself by using hundreds of data points to assess insurance risk instead of relying on the limited variables traditionally used by insurance companies. This allows the company to price policies more accurately and increase operational efficiency. Its proprietary technology automates a significant part of the insurance process, including pricing and underwriting support, customer service, and claims management. The platform continuously learns from customer data, helping to improve pricing accuracy and reduce operating costs over time.
The company's financial results reflect this approach: Ominimo's annual gross premium revenue growth rate increased from 26.3 million euros in 2024 to approximately 307 million euros to date. The company serves nearly a million customers across various European markets while remaining profitable. Staff numbers have also grown rapidly: from about 40 people in the early stages to approximately 130 today, with plans to reach 150 employees by the end of the year.
Unlike many insurtech companies, Ominimo prioritized sustainable growth over aggressive expansion and weak financial operations. Its strategy involved partnering with existing insurers while simultaneously improving technology and operational capabilities for long-term success. This approach ensured steady growth, fostering strong partnerships with insurers such as Signal Iduna and DA Direkt. These partnerships have enhanced the customer experience, pricing models, and operational performance of the company across numerous global insurance markets. Investors remained confident as Ominimo consistently demonstrated strong business execution throughout its growth and expansion history. After being valued at $200 million during its Series A round in 2025, Ominimo successfully achieved unicorn status.
The Stockholm-based healthtech company Neko Health has successfully raised $700 million in a Series C funding round. The company's mission is to create a new healthcare system focused on early disease detection and disease prevention. The firm was founded by Daniel Ek, co-founder of Spotify.
The Neko Health project is based on futuristic 60-minute scanning. Imagine a modern, relaxing clinic where a body scan takes about an hour, is completely safe, and does not use radiation. The cost of such a scan is £299 in the UK and 2750 Swedish Kronor in Sweden.
Neko's scanning is possible through the use of specially designed sensors and rapid blood analysis. This procedure allows for an assessment of the cardiovascular, metabolic, and skin systems. It meticulously examines moles, detects signs of prediabetes, and identifies stroke risk factors. In just minutes, the user receives a detailed digital map of their body and can then discuss the results with a doctor in person, eliminating the stressful wait of the traditional medical system. Over 100,000 people have already used this service.
Unlike many other medical companies, Neko develops all components of its technological base internally. The company manufactures its own hardware and software in Sweden. Last month, Neko unveiled its latest clinical devices: Derma-2, Echo-2, and Spectrum-2. These modernized devices are capable of capturing a significantly larger volume of biological signals from the skin, heart, and circulatory system. Furthermore, they have added real-time body composition analysis and the ability for clinicians to view data from wearable devices, deepening the continuous picture of the user's health. Thanks to this internal focus, the team can automate processes and quickly implement updates across all clinics.
The $700 million raised by Neko did not come only from venture capital. The startup received investments from tech giants such as Mark Zuckerberg and Priscilla Chan, as well as celebrities including Maria Sharapova, Thierry Henry, will.i.am, and Tim Ferriss. The round was also supported by Hollywood heavyweights Ari Emanuel and music director Jimmy Iovine. Investors are highly interested because Neko is at the intersection of artificial intelligence and is preparing to enter the US market after successfully validating its model in Sweden and London.
Neko plans to open its first clinics in the US in New York later this year. The company has already received FDA approval for several key products. Ek, who previously left his position as CEO of Spotify, is applying his experience in international music expansion to the healthcare sector. He acknowledged that the transition from Sweden to the UK was challenging, but facing the complex US healthcare landscape will be ten times harder. Nevertheless, there is a queue of over 350,000 people, which underscores the obvious need for the services. The platform demonstrates measurable results: early detection has led to real improvements in condition, with three out of four regular clients being able to keep identified issues under control.
